Cargando…
The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov
BACKGROUND: As medication expenditures rise, payers are increasingly demanding evidence of economic value for new medications. The 2015 Professional Society for Health Economics and Outcomes Research (ISPOR) Task Force on Cost-Effectiveness Analysis Alongside Clinical Trials noted that clinical tria...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391117/ https://www.ncbi.nlm.nih.gov/pubmed/32223593 http://dx.doi.org/10.18553/jmcp.2020.26.4.386 |